These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10787686)

  • 1. An analysis of 1997 healthcare initial public offerings.
    Palkon DS
    Hosp Top; 1999; 77(3):22-7. PubMed ID: 10787686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public markets show signs of life.
    Mitchell P
    Nat Biotechnol; 2003 Aug; 21(8):833-4. PubMed ID: 12894181
    [No Abstract]   [Full Text] [Related]  

  • 3. Korean biotechs seize opportunity to list on public markets.
    Louët S
    Nat Biotechnol; 2005 Oct; 23(10):1189-90. PubMed ID: 16211042
    [No Abstract]   [Full Text] [Related]  

  • 4. Dualistic healthcare markets: the impact of boutique offerings.
    Stanfill PH
    J Oncol Manag; 2000; 9(4):13-20. PubMed ID: 11186507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public companies get creative in raising finance.
    Hodgson J
    Nat Biotechnol; 2010 Apr; 28(4):301-2. PubMed ID: 20379161
    [No Abstract]   [Full Text] [Related]  

  • 6. Using real-estate-based financing to access capital.
    Tobin WC; Kryzaniak LA
    Healthc Financ Manage; 1998 Jul; 52(7):58-60. PubMed ID: 10180896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future trends in the health care economy.
    Kajander J; Samuels M
    J Health Care Finance; 1996; 23(1):17-22. PubMed ID: 8889976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Going strong, going public. Despite spate of chronic problems and calls for reform, healthcare initial public offerings demonstrate fiscal health.
    Zigmond J
    Mod Healthc; 2007 Dec 24-31; 37(51):6-7, 16, 1. PubMed ID: 18220122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IPOs: the narrow window closes?
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1489. PubMed ID: 15583641
    [No Abstract]   [Full Text] [Related]  

  • 10. Financing development stage biotechnology companies: RMs vs. IPOs.
    Ahn MJ; Couch RB; Wu W
    J Health Care Finance; 2011; 38(1):32-54. PubMed ID: 22043645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Companies jostle for access to public markets.
    Bouchie A
    Nat Biotechnol; 2003 Dec; 21(12):1413-4. PubMed ID: 14647309
    [No Abstract]   [Full Text] [Related]  

  • 12. The responsibilities of growing up.
    Nat Biotechnol; 2006 Mar; 24(3):225. PubMed ID: 16525362
    [No Abstract]   [Full Text] [Related]  

  • 13. Biotech IPOs: handle with care.
    Jacobs T
    Nat Biotechnol; 2003 Dec; 21(12):1437. PubMed ID: 14647322
    [No Abstract]   [Full Text] [Related]  

  • 14. Biotech IPOs--flop or pop?
    Jacobs T
    Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641
    [No Abstract]   [Full Text] [Related]  

  • 15. Public sector seeks to bridge 'valley of death'.
    Moran N
    Nat Biotechnol; 2007 Mar; 25(3):266. PubMed ID: 17344867
    [No Abstract]   [Full Text] [Related]  

  • 16. The future of physician practice management companies.
    Thomas MS
    Healthc Financ Manage; 1997 Aug; 51(8):71-4. PubMed ID: 10168710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diversa restructures, raising question over bioprospecting.
    Sheridan C
    Nat Biotechnol; 2006 Mar; 24(3):229. PubMed ID: 16525364
    [No Abstract]   [Full Text] [Related]  

  • 18. SADA communique. Competition Commission.
    Smit M
    SADJ; 2013 Jun; 68(5):204. PubMed ID: 23971284
    [No Abstract]   [Full Text] [Related]  

  • 19. Health care industry trends: converting data to competitive advantage.
    Kaufman K; Tkach S
    Trustee; 2007 Feb; 60(2):24-8, 2. PubMed ID: 17370743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The death spiral.
    Nat Biotechnol; 2006 Jun; 24(6):594. PubMed ID: 16763571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.